Episode

Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water

Podcast: BioSpace
Published: Jul 1, 2026
Duration seconds: 1374
Processing state: not_requested
Canonical source: https://api.riverside.com/hosting-analytics/media/d71aab074556b860062ff88723341d147218d8383bcd3182383c9739bfc92046/eyJlcGlzb2RlSWQiOiJiY2IzNzE4Ni00ZmQwLTQxZWMtOTgxYy02M2Y3ZjkyNjFiMGQiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmE0NDBlNWI1ZTk4OGU0ZmQ2MDEzOTI2L2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTMwX18yMC00My0zOS5tcDMifQ==.mp3
Audio: https://api.riverside.com/hosting-analytics/media/d71aab074556b860062ff88723341d147218d8383bcd3182383c9739bfc92046/eyJlcGlzb2RlSWQiOiJiY2IzNzE4Ni00ZmQwLTQxZWMtOTgxYy02M2Y3ZjkyNjFiMGQiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmE0NDBlNWI1ZTk4OGU0ZmQ2MDEzOTI2L2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTMwX18yMC00My0zOS5tcDMifQ==.mp3
JSON: /v1/public/podcasts/biospace-6696251/episodes/sentiment-at-bio-soars-as-fda-resets-dealmaking-evolves-amgen-s-tavneos-in-hot-water
Markdown: /podcast/biospace-6696251/sentiment-at-bio-soars-as-fda-resets-dealmaking-evolves-amgen-s-tavneos-in-hot-water.md

Actions

POST https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/sentiment-at-bio-soars-as-fda-resets-dealmaking-evolves-amgen-s-tavneos-in-hot-water/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/biospace-6696251/sentiment-at-bio-soars-as-fda-resets-dealmaking-evolves-amgen-s-tavneos-in-hot-water.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

The vibe at BIO 2026 in San Diego last week was overwhelmingly positive, with attendees observing noticeable changes at the FDA and an uptick in dealmaking and IPOs. Plus, a top medical journal this week retracted a pivotal study for Amgen’s rare disease drug Tavneos, which has been in the FDA’s crosshairs since January.